[Vorasidenib for low-grade gliomas-new treatment option with unanswered questions regarding long-term outcomes].
作者信息
Seidel Clemens, Nicolay Nils H
机构信息
Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Leipzig, Stephanstraße 9a, 04103, Leipzig, Deutschland.
出版信息
Strahlenther Onkol. 2024 Feb;200(2):178-180. doi: 10.1007/s00066-023-02179-2. Epub 2023 Nov 20.
Abstract
摘要
相似文献
1
[Vorasidenib for low-grade gliomas-new treatment option with unanswered questions regarding long-term outcomes].[伏立昔替尼治疗低级别胶质瘤——一种新的治疗选择，但长期疗效仍存在疑问]
Strahlenther Onkol. 2024 Feb;200(2):178-180. doi: 10.1007/s00066-023-02179-2. Epub 2023 Nov 20.
2
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.沃拉西尼布，一种 IDH1/2 突变体的双重抑制剂，用于复发性或进行性脑胶质瘤；一项首次人体 I 期试验的结果。
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.
3
The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.氨基酸PET成像在预测和监测异柠檬酸脱氢酶（IDH）突变型胶质瘤中伏立西尼反应方面的潜力。
Neuro Oncol. 2024 Mar 4;26(3):403-406. doi: 10.1093/neuonc/noad240.
4
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
5
Vorasidenib; a new hope for managing gliomas after surgery?沃拉西尼布；手术后治疗神经胶质瘤的新希望？
Neurosurg Rev. 2024 Oct 4;47(1):732. doi: 10.1007/s10143-024-03011-w.
6
Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma.准备进入INDIGO：伏立西尼开启低级别胶质瘤异柠檬酸脱氢酶抑制时代。
Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):334-336. doi: 10.1016/j.ijrobp.2023.10.045.
7
Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.伏立西替尼——IDH1或IDH2突变型低级别胶质瘤治疗的范式转变。
J Pak Med Assoc. 2024 Oct;74(10):1912-1913. doi: 10.47391/JPMA.20428.
8
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.沃拉西尼布和伊沃西尼布治疗 IDH1 突变型低级别胶质瘤：一项随机、围手术期的 1 期临床试验。
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
9
A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma.一项有前景的突破：伏立昔替尼治疗低级别胶质瘤的潜力
Curr Mol Pharmacol. 2024 Feb 29. doi: 10.2174/0118761429290327240222061812.
10
A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.漫长等待后的新时代：伏立西尼，一种用于异柠檬酸脱氢酶（IDH）突变型胶质瘤患者的突变型IDH1和IDH2酶抑制剂。
Tumori. 2024 Jun;110(3):160-161. doi: 10.1177/03008916231217583. Epub 2024 Jan 2.
本文引用的文献
1
Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.成人脑胶质瘤患者多模态治疗后的长期神经认知功能和生活质量：前瞻性长期随访。
J Neurooncol. 2023 Sep;164(2):353-366. doi: 10.1007/s11060-023-04419-y. Epub 2023 Aug 30.
2
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
3
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.沃拉西尼布和伊沃西尼布治疗 IDH1 突变型低级别胶质瘤：一项随机、围手术期的 1 期临床试验。
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
4
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.沃拉西尼布，一种 IDH1/2 突变体的双重抑制剂，用于复发性或进行性脑胶质瘤；一项首次人体 I 期试验的结果。
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.
5
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.意大利神经肿瘤学会（Italian Association for Neuro-Oncology）一项 II 期研究中初始替莫唑胺治疗高危低级别胶质瘤的疗效：根据 2016 年 WHO 分子亚组的事后分析。
J Neurooncol. 2019 Oct;145(1):115-123. doi: 10.1007/s11060-019-03277-x. Epub 2019 Sep 25.
6
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.替莫唑胺化疗与放疗治疗高危低级别胶质瘤的对比研究（欧洲癌症研究与治疗组织22033-26033）：一项随机、开放标签的3期组间研究。
Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.
7
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.放疗联合丙卡巴肼、洛莫司汀和长春新碱治疗低级别胶质瘤
N Engl J Med. 2016 Apr 7;374(14):1344-55. doi: 10.1056/NEJMoa1500925.
8
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.IDH1 突变足以建立起胶质瘤高甲基化表型。
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
9
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.低级别胶质瘤患者放疗的认知和放射学效应：长期随访
Lancet Neurol. 2009 Sep;8(9):810-8. doi: 10.1016/S1474-4422(09)70204-2. Epub 2009 Aug 7.
10
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.放疗及其他治疗相关因素对低级别胶质瘤中期至长期认知后遗症的影响：一项对比研究。
Lancet. 2002 Nov 2;360(9343):1361-8. doi: 10.1016/s0140-6736(02)11398-5.
Zotero 插件